Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:46 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
NCT04892446 · Gilead Sciences · PHASE2 · terminated · last registry update 2025-05-02 · Multiple myeloma · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “This study was terminated early due to the Sponsor's decision to discontinue development of the investigational drug and close the program.” | Open Targets' class: business administrative | Registry record, Gilead Sciences |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD47 in multiple myeloma within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
No results, stops or Phase 3 starts on the same target in that window.
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision